Ellen Neylon

752 total citations
27 papers, 571 citations indexed

About

Ellen Neylon is a scholar working on Pathology and Forensic Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Ellen Neylon has authored 27 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 13 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Ellen Neylon's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Histone Deacetylase Inhibitors Research (5 papers). Ellen Neylon is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Histone Deacetylase Inhibitors Research (5 papers). Ellen Neylon collaborates with scholars based in United States, Denmark and United Kingdom. Ellen Neylon's co-authors include Owen A. O’Connor, Paul A. Hamlin, Andrew D. Zelenetz, Craig H. Moskowitz, Debra Sarasohn, Carol S. Portlock, Barbara MacGregor‐Cortelli, Diane R. Mould, Steven M. Horwitz and David J. Straus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Ellen Neylon

26 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Neylon United States	12	371	227	167	156	144	27	571
Ana Carolina da Silva Almeida Brazil	8	245 0.7×	181 0.8×	189 1.1×	153 1.0×	191 1.3×	16	529
Matko Kalac United States	9	161 0.4×	148 0.7×	89 0.5×	220 1.4×	53 0.4×	37	423
Antonia Rodríguez Spain	10	284 0.8×	179 0.8×	99 0.6×	269 1.7×	24 0.2×	14	595
Laurianne Scourzic France	8	193 0.5×	157 0.7×	154 0.9×	287 1.8×	29 0.2×	9	545
Elodie Laharanne France	12	269 0.7×	158 0.7×	119 0.7×	114 0.7×	269 1.9×	22	494
Yoshikazu Sasaki Japan	11	272 0.7×	184 0.8×	79 0.5×	94 0.6×	29 0.2×	23	491
Shivakumar Subramaniyam United States	10	147 0.4×	177 0.8×	44 0.3×	350 2.2×	38 0.3×	21	624
Gillian Turner United Kingdom	8	266 0.7×	234 1.0×	65 0.4×	107 0.7×	16 0.1×	13	531
RM Braziel United States	4	330 0.9×	221 1.0×	53 0.3×	74 0.5×	21 0.1×	5	434
JK Larsen Denmark	12	227 0.6×	102 0.4×	196 1.2×	86 0.6×	30 0.2×	17	448

Countries citing papers authored by Ellen Neylon

Since Specialization

Citations

This map shows the geographic impact of Ellen Neylon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Neylon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Neylon more than expected).

Fields of papers citing papers by Ellen Neylon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Neylon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Neylon. The network helps show where Ellen Neylon may publish in the future.

Co-authorship network of co-authors of Ellen Neylon

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Neylon. A scholar is included among the top collaborators of Ellen Neylon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Neylon. Ellen Neylon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Neylon, Ellen, et al.. (2016). Updates in Chemotherapy-Induced Nausea and Vomiting: The Oncology Nurse and Oncology Nurse Practitioner's Perspectives. Seminars in Oncology Nursing. 32(2). 183–183. 1 indexed citations

Sawas, Ahmed, Joseph M. Connors, John Kuruvilla, et al.. (2015). The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience. Blood. 126(23). 586–586. 11 indexed citations

O’Connor, Owen A., Kelly Zullo, Enrica Marchi, et al.. (2015). Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development. Blood. 126(23). 1282–1282. 2 indexed citations

LeBlanc, Thomas W., et al.. (2015). Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma. Blood. 126(23). 5634–5634. 1 indexed citations

Sawas, Ahmed, et al.. (2013). A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma. Blood. 122(21). 5134–5134. 2 indexed citations

Amengual, Jennifer E., Sean Clark-Garvey, Matko Kalac, et al.. (2012). Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.. Blood. 120(21). 2725–2725. 1 indexed citations

Zain, Jasmine, Francine M. Foss, Catherine Diefenbach, et al.. (2011). Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,. Blood. 118(21). 3710–3710. 5 indexed citations

Zain, Jasmine, Francine M. Foss, Johann S. de Bono, et al.. (2010). Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.. Blood. 116(21). 1787–1787. 1 indexed citations

O’Connor, Owen A., Steven M. Horwitz, Paul A. Hamlin, et al.. (2009). Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. Journal of Clinical Oncology. 27(26). 4357–4364. 131 indexed citations

10.

Gerecitano, John F., Carol S. Portlock, Craig H. Moskowitz, et al.. (2009). Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology. 146(6). 652–655. 39 indexed citations

11.

Mould, Diane R., Kevin Sweeney, Stephen B. Duffull, et al.. (2009). A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non-Hodgkin's or Hodgkin's Lymphoma. Clinical Pharmacology & Therapeutics. 86(2). 190–196. 28 indexed citations

12.

Zain, Jasmine, Francine M. Foss, William Kevin Kelly, et al.. (2009). Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. Journal of Clinical Oncology. 27(15_suppl). 8580–8580. 13 indexed citations

13.

Pro, Barbara, Bertrand Coiffier, Sarah McCue Horwitz, et al.. (2009). Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis.. Blood. 114(22). 1681–1681. 4 indexed citations

14.

O’Connor, Owen A., Craig H. Moskowitz, Carol S. Portlock, et al.. (2009). Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. British Journal of Haematology. 145(1). 34–39. 59 indexed citations

15.

O’Connor, Owen A., Paul A. Hamlin, Carol S. Portlock, et al.. (2007). Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma. British Journal of Haematology. 139(3). 425–428. 68 indexed citations

16.

Mould, Diane R., Kevin Sweeney, Stephen B. Duffull, Ellen Neylon, & Owen A. O’Connor. (2007). A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.. Blood. 110(11). 1370–1370. 3 indexed citations

17.

Gerecitano, John F., André Goy, James R. Wright, et al.. (2006). Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology. 134(4). 391–398. 36 indexed citations

18.

Gerecitano, John F., Carol S. Portlock, Ariela Noy, et al.. (2006). The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.. Blood. 108(11). 2759–2759. 6 indexed citations

19.

Hamlin, Paul A., Ellen Neylon, Craig H. Moskowitz, et al.. (2005). Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.. Blood. 106(11). 2678–2678. 6 indexed citations

20.

O’Connor, Owen A., David J. Straus, Craig H. Moskowitz, et al.. (2005). Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease. Journal of Clinical Oncology. 23(16_suppl). 6569–6569. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact